Sonoma Pharmaceuticals, which develops treatments for dermatological conditions and advanced wound care with its flagship product stabilized hypochlorous acid, slid almost 14% in pre-market trading today, Wednesday, August 28. This follows an announced reverse stock split to maintain the company’s listing. Details In trading before the open on Wednesday, Sonoma…